Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Pfizer pledges $100M to new Antimicrobial Resistance Action Fund » 15:23
07/09/20
07/09
15:23
07/09/20
15:23
PFE

Pfizer

$33.57 /

-0.19 (-0.56%)

, AMGN

Amgen

$252.34 /

+0.74 (+0.29%)

, BAYRY

Bayer

$0.00 /

+ (+0.00%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, LLY

Eli Lilly

$166.59 /

-2.52 (-1.49%)

, GSK

GlaxoSmithKline

$40.37 /

-0.35 (-0.86%)

, MRK

Merck

$76.99 /

-0.88 (-1.13%)

, MKGAY

Merck KGaA

$0.00 /

+ (+0.00%)

, TEVA

Teva

$11.60 /

+0.21 (+1.84%)

, TAK

Takeda Pharmaceutical

$17.36 /

-0.135 (-0.77%)

, NVO

Novo Nordisk

$65.63 /

-0.23 (-0.35%)

, JNJ

Johnson & Johnson

$143.03 /

-0.21 (-0.15%)

, NVS

Novartis

$87.53 /

-0.585 (-0.66%)

Pfizer (PFE) announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
PFE Pfizer
$33.57 /

-0.19 (-0.56%)

AMGN Amgen
$252.34 /

+0.74 (+0.29%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

LLY Eli Lilly
$166.59 /

-2.52 (-1.49%)

GSK GlaxoSmithKline
$40.37 /

-0.35 (-0.86%)

MRK Merck
$76.99 /

-0.88 (-1.13%)

MKGAY Merck KGaA
$0.00 /

+ (+0.00%)

TEVA Teva
$11.60 /

+0.21 (+1.84%)

TAK Takeda Pharmaceutical
$17.36 /

-0.135 (-0.77%)

NVO Novo Nordisk
$65.63 /

-0.23 (-0.35%)

JNJ Johnson & Johnson
$143.03 /

-0.21 (-0.15%)

NVS Novartis
$87.53 /

-0.585 (-0.66%)

PFE Pfizer
$33.57 /

-0.19 (-0.56%)

07/08/20 Piper Sandler
Opko Health price target raised to $6 from $4 at Piper Sandler
07/08/20 Argus
Pfizer positioned for stronger revenue growth in 2021 and beyond, says Argus
07/07/20 Needham
Vaxcyte initiated with a Buy at Needham
07/02/20 B. Riley FBR
Novavax should be bought on weakness from Pfizer data, says B. Riley FBR
AMGN Amgen
$252.34 /

+0.74 (+0.29%)

07/02/20 Citi
Citi sees 'considerable amount of investor interest' coming back to Amgen
07/01/20 Piper Sandler
Amgen appeal rules in favor of patent validity, says Piper Sandler
07/01/20 Mizuho
Amgen patent win worth $5-$12 per share, says Mizuho
07/01/20 Goldman Sachs
Court ruling removes overhang for Amgen, says Goldman Sachs
BAYRY Bayer
$0.00 /

+ (+0.00%)

06/26/20 JPMorgan
Bayer price target raised to EUR 77 from EUR 75 at JPMorgan
06/26/20 Deutsche Bank
Bayer price target raised to EUR 87 from EUR 85 at Deutsche Bank
06/25/20 Morgan Stanley
Bayer price target raised to EUR 88 from EUR 83 at Morgan Stanley
06/25/20 HSBC
HSBC upgrades Bayer to Buy after settlement on most Monsanto cases in U.S.
RHHBY Roche
$0.00 /

+ (+0.00%)

07/03/20 AlphaValue
Roche upgraded to Add from Reduce at AlphaValue
06/29/20 Piper Sandler
Herceptin/Perjecta approval another win for Halozyme, says Piper
06/23/20 Guggenheim
Immunomedics could be M&A fit for several large-cap drugmakers, says Guggenheim
06/10/20 SunTrust
Arcus Biosciences price target raised to $45 from $22 at SunTrust
LLY Eli Lilly
$166.59 /

-2.52 (-1.49%)

10:13 Today Morgan Stanley
Eli Lilly won't publish Phase 1 COVID antibody data, says Morgan Stanley
06/29/20 Mizuho
Eli Lilly price target raised to $164 from $155 at Mizuho
06/23/20 Guggenheim
Immunomedics could be M&A fit for several large-cap drugmakers, says Guggenheim
06/17/20 JPMorgan
Eli Lilly price target raised to $190 from $175 at JPMorgan
GSK GlaxoSmithKline
$40.37 /

-0.35 (-0.86%)

06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
06/19/20 Barclays
Glaxo belantamab AdCom a surprise, supports cautious view, says Barclays
06/16/20 Roth Capital
Ideaya Biosciences price target raised to $23 from $12 at Roth Capital
05/14/20 UBS
GlaxoSmithKline price target raised to 1,920 GBp from 1,900 GBp at UBS
MRK Merck
$76.99 /

-0.88 (-1.13%)

06/30/20 SVB Leerink
Seattle Genetics price target raised to $167 from $155 at SVB Leerink
06/30/20 Oppenheimer
Seattle Genetics price target raised to $210 from $200 at Oppenheimer
06/25/20 Lake Street
Lake Street says Keytruda approval improves outlook for Checkpoint's cosibelimab
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
MKGAY Merck KGaA
$0.00 /

+ (+0.00%)

05/15/20 Nord/LB
Merck KGaA downgraded to Hold from Buy at Nord/LB
03/06/20 UBS
UBS backs Neutral on Merck KGaA after Q4 results
12/02/19 Goldman Sachs
Merck KGaA reinstated with a Sell at Goldman Sachs
10/04/19 Loop Capital
Entegris price target raised to $51 from $47 at Loop Capital
TEVA Teva
$11.60 /

+0.21 (+1.84%)

07/02/20 Wells Fargo
Emergent BioSolutions price target raised to $93 from $85 at Wells Fargo
06/26/20 William Blair
Pfenex partner CHMP opinion 'material de-risking event,' says William Blair
06/17/20 Stifel
Amarin settlement with Apotex an 'incremental positive,' says Stifel
06/08/20 Guggenheim
Emergent BioSolutions price target lowered to $87 from $101 at Guggenheim
TAK Takeda Pharmaceutical
$17.36 /

-0.135 (-0.77%)

06/18/20 RBC Capital
Neurocrine price target raised to $135 from $116 at RBC Capital
06/17/20 Oppenheimer
Takeda deal expands Neurocrine's pipeline into psychiatry, says Oppenheimer
04/20/20 SVB Leerink
Ascendis Pharma price target raised to $170 from $152 at SVB Leerink
03/25/20 Piper Sandler
Piper Sandler backs Overweight on 'well capitalized' Exelixis
NVO Novo Nordisk
$65.63 /

-0.23 (-0.35%)

07/06/20 BofA
Novo Nordisk downgraded to Neutral from Buy at BofA
06/05/20 JPMorgan
JPMorgan backs Overweight on Novo Nordisk after STEP data
05/18/20 Morgan Stanley
Novo Nordisk price target raised to DKK 435 from DKK 425 at Morgan Stanley
05/13/20 JPMorgan
Novo Nordisk price target raised to DKK 480 from DKK 460 at JPMorgan
JNJ Johnson & Johnson
$143.03 /

-0.21 (-0.15%)

07/06/20 Baird
Cooper Companies downgraded to Neutral, Baird see confluence of issues
07/01/20 JMP Securities
Minerva's seltorexant still 'underappreciated' upside driver, says JMP
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
05/29/20 H.C. Wainwright
H.C. Wainwright sees path forward for Minerva's roluperidone despite setback
NVS Novartis
$87.53 /

-0.585 (-0.66%)

07/01/20 Piper Sandler
Amgen appeal rules in favor of patent validity, says Piper Sandler
07/01/20 Jefferies
Amgen win on Enbrel patent removes key overhang, says Jefferies
07/01/20 Goldman Sachs
Global Blood Therapeutics upgraded to Buy from Neutral at Goldman Sachs
06/24/20 Morgan Stanley
Novartis' syringe suit not a material threat to Regeneron, says Morgan Stanley
PFE Pfizer
$33.57 /

-0.19 (-0.56%)

AMGN Amgen
$252.34 /

+0.74 (+0.29%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

LLY Eli Lilly
$166.59 /

-2.52 (-1.49%)

GSK GlaxoSmithKline
$40.37 /

-0.35 (-0.86%)

MRK Merck
$76.99 /

-0.88 (-1.13%)

TEVA Teva
$11.60 /

+0.21 (+1.84%)

NVO Novo Nordisk
$65.63 /

-0.23 (-0.35%)

JNJ Johnson & Johnson
$143.03 /

-0.21 (-0.15%)

NVS Novartis
$87.53 /

-0.585 (-0.66%)

PFE Pfizer
$33.57 /

-0.19 (-0.56%)

AMGN Amgen
$252.34 /

+0.74 (+0.29%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

LLY Eli Lilly
$166.59 /

-2.52 (-1.49%)

GSK GlaxoSmithKline
$40.37 /

-0.35 (-0.86%)

MRK Merck
$76.99 /

-0.88 (-1.13%)

MKGAY Merck KGaA
$0.00 /

+ (+0.00%)

TEVA Teva
$11.60 /

+0.21 (+1.84%)

TAK Takeda Pharmaceutical
$17.36 /

-0.135 (-0.77%)

NVO Novo Nordisk
$65.63 /

-0.23 (-0.35%)

JNJ Johnson & Johnson
$143.03 /

-0.21 (-0.15%)

NVS Novartis
$87.53 /

-0.585 (-0.66%)

PFE Pfizer
$33.57 /

-0.19 (-0.56%)

AMGN Amgen
$252.34 /

+0.74 (+0.29%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

LLY Eli Lilly
$166.59 /

-2.52 (-1.49%)

GSK GlaxoSmithKline
$40.37 /

-0.35 (-0.86%)

MRK Merck
$76.99 /

-0.88 (-1.13%)

TEVA Teva
$11.60 /

+0.21 (+1.84%)

TAK Takeda Pharmaceutical
$17.36 /

-0.135 (-0.77%)

NVO Novo Nordisk
$65.63 /

-0.23 (-0.35%)

JNJ Johnson & Johnson
$143.03 /

-0.21 (-0.15%)

NVS Novartis
$87.53 /

-0.585 (-0.66%)

PFE Pfizer
$33.57 /

-0.19 (-0.56%)

AMGN Amgen
$252.34 /

+0.74 (+0.29%)

LLY Eli Lilly
$166.59 /

-2.52 (-1.49%)

GSK GlaxoSmithKline
$40.37 /

-0.35 (-0.86%)

MRK Merck
$76.99 /

-0.88 (-1.13%)

TEVA Teva
$11.60 /

+0.21 (+1.84%)

TAK Takeda Pharmaceutical
$17.36 /

-0.135 (-0.77%)

JNJ Johnson & Johnson
$143.03 /

-0.21 (-0.15%)

NVS Novartis
$87.53 /

-0.585 (-0.66%)

Hot Stocks
Moderna enters collaboration with ROVI » 08:10
07/09/20
07/09
08:10
07/09/20
08:10
MRNA

Moderna

$61.54 /

+0.46 (+0.75%)

Moderna and Laboratorios…

Moderna and Laboratorios Farmaceuticos Rovi announced a collaboration for large-scale, commercial fill-finish manufacturing of Moderna's mRNA vaccine candidate against COVID-19 (mRNA-1273) at ROVI's facility in Madrid, Spain. The companies said in a release, "As part of the agreement, ROVI will provide vial filling and packaging capacity by procuring a new production line and equipment for compounding, filling, automatic visual inspection and labeling to support production of hundreds of millions of doses of the vaccine candidate intended in principle to supply markets outside of the U.S. starting in early 2021. ROVI will also hire additional staffing required to support manufacturing operations and production."

ShowHide Related Items >><<
MRNA Moderna
$61.54 /

+0.46 (+0.75%)

MRNA Moderna
$61.54 /

+0.46 (+0.75%)

07/08/20 Piper Sandler
Piper reiterates $100 target on Moderna after Phase II study enrolled
07/02/20 BMO Capital
Moderna mRNA platform supported by Pfizer vaccine data, says BMO Capital
06/30/20 Argus
Moderna initiated with a Buy at Argus
06/30/20 Argus
Moderna initiated with a Buy at Argus
MRNA Moderna
$61.54 /

+0.46 (+0.75%)

  • 19
    May
  • 12
    Feb
MRNA Moderna
$61.54 /

+0.46 (+0.75%)

MRNA Moderna
$61.54 /

+0.46 (+0.75%)

MRNA Moderna
$61.54 /

+0.46 (+0.75%)

Hot Stocks
AstraZeneca reports Brilinta sNDA accepted, granted FDA Priority Review » 06:49
07/09/20
07/09
06:49
07/09/20
06:49
AZN

AstraZeneca

$54.19 /

+0.7 (+1.31%)

AstraZeneca announced the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
AZN AstraZeneca
$54.19 /

+0.7 (+1.31%)

AZN AstraZeneca
$54.19 /

+0.7 (+1.31%)

06/24/20 Oddo BHF
AstraZeneca downgraded to Reduce from Buy at Oddo BHF
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
06/10/20 Cowen
AstraZeneca price target raised to $60 from $55 at Cowen
06/10/20 Guggenheim
Merck's bladder cancer failure boosts strategic value of Padcev, says Guggenheim
AZN AstraZeneca
$54.19 /

+0.7 (+1.31%)

AZN AstraZeneca
$54.19 /

+0.7 (+1.31%)

AZN AstraZeneca
$54.19 /

+0.7 (+1.31%)

AZN AstraZeneca
$54.19 /

+0.7 (+1.31%)

Hot Stocks
Ideaya doses first patient in Phase 1 combination study of IDE196/binimetinib » 06:06
07/09/20
07/09
06:06
07/09/20
06:06
IDYA

Ideaya Biosciences

$13.80 /

+0.32 (+2.37%)

, PFE

Pfizer

$33.76 /

-0.27 (-0.79%)

IDEAYA Biosciences (IDYA)…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
PFE Pfizer
$33.76 /

-0.27 (-0.79%)

IDYA Ideaya Biosciences
$13.80 /

+0.32 (+2.37%)

IDYA Ideaya Biosciences
$13.80 /

+0.32 (+2.37%)

06/17/20 H.C. Wainwright
Ideaya Biosciences price target raised to $22 from $13 at H.C. Wainwright
06/16/20 Roth Capital
Ideaya Biosciences price target raised to $23 from $12 at Roth Capital
06/16/20 Oppenheimer
Ideaya Biosciences price target raised to $25 from $17 at Oppenheimer
04/06/20
Fly Intel: Top five analyst initiations
PFE Pfizer
$33.76 /

-0.27 (-0.79%)

07/08/20 Piper Sandler
Opko Health price target raised to $6 from $4 at Piper Sandler
07/08/20 Argus
Pfizer positioned for stronger revenue growth in 2021 and beyond, says Argus
07/07/20 Needham
Vaxcyte initiated with a Buy at Needham
07/02/20 B. Riley FBR
Novavax should be bought on weakness from Pfizer data, says B. Riley FBR
PFE Pfizer
$33.76 /

-0.27 (-0.79%)

IDYA Ideaya Biosciences
$13.80 /

+0.32 (+2.37%)

  • 18
    Jun
PFE Pfizer
$33.76 /

-0.27 (-0.79%)

PFE Pfizer
$33.76 /

-0.27 (-0.79%)

IDYA Ideaya Biosciences
$13.80 /

+0.32 (+2.37%)

PFE Pfizer
$33.76 /

-0.27 (-0.79%)

Conference/Events
Oxford Global Marketing to hold a virtual event » 04:55
07/09/20
07/09
04:55
07/09/20
04:55
ABBV

AbbVie

$99.28 /

-0.06 (-0.06%)

, AZN

AstraZeneca

$54.19 /

+0.7 (+1.31%)

, BAYRY

Bayer

$0.00 /

+ (+0.00%)

, BMY

Bristol-Myers

$59.58 /

-0.72 (-1.19%)

, GSK

GlaxoSmithKline

$40.72 /

+0.34 (+0.84%)

, IPSEY

Ipsen

$0.00 /

+ (+0.00%)

, JAZZ

Jazz Pharmaceuticals

$107.54 /

-1.18 (-1.09%)

, JNJ

Johnson & Johnson

$143.24 /

+0.43 (+0.30%)

, NVS

Novartis

$88.12 /

+0.345 (+0.39%)

, PFE

Pfizer

$33.76 /

-0.27 (-0.79%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, RTRX

Retrophin

$20.86 /

-0.04 (-0.19%)

, SNY

Sanofi

$51.54 /

+0.14 (+0.27%)

, TAK

Takeda Pharmaceutical

$17.49 /

+0.01 (+0.06%)

, TEVA

Teva

$11.39 /

+0.17 (+1.52%)

Formulation &…

Formulation & Delivery Series Biomanufacturing Virtual Congress will be held on July 8-9. Webcast Link

ShowHide Related Items >><<
TEVA Teva
$11.39 /

+0.17 (+1.52%)

TAK Takeda Pharmaceutical
$17.49 /

+0.01 (+0.06%)

SNY Sanofi
$51.54 /

+0.14 (+0.27%)

RTRX Retrophin
$20.86 /

-0.04 (-0.19%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$33.76 /

-0.27 (-0.79%)

NVS Novartis
$88.12 /

+0.345 (+0.39%)

JNJ Johnson & Johnson
$143.24 /

+0.43 (+0.30%)

JAZZ Jazz Pharmaceuticals
$107.54 /

-1.18 (-1.09%)

IPSEY Ipsen
$0.00 /

+ (+0.00%)

GSK GlaxoSmithKline
$40.72 /

+0.34 (+0.84%)

BMY Bristol-Myers
$59.58 /

-0.72 (-1.19%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$54.19 /

+0.7 (+1.31%)

ABBV AbbVie
$99.28 /

-0.06 (-0.06%)

ABBV AbbVie
$99.28 /

-0.06 (-0.06%)

07/07/20 SunTrust
Evolus price target lowered to $6 from $12 at SunTrust
07/06/20 Piper Sandler
Biohaven launch of Nurtec 'continues to impress,' says Piper Sandler
06/29/20 Mizuho
AbbVie price target raised to $110 from $101 at Mizuho
06/26/20 Raymond James
Adverum Biotechnologies downgradedat Raymond James on abicipar CRL
AZN AstraZeneca
$54.19 /

+0.7 (+1.31%)

06/24/20 Oddo BHF
AstraZeneca downgraded to Reduce from Buy at Oddo BHF
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
06/10/20 Cowen
AstraZeneca price target raised to $60 from $55 at Cowen
06/10/20 Guggenheim
Merck's bladder cancer failure boosts strategic value of Padcev, says Guggenheim
BAYRY Bayer
$0.00 /

+ (+0.00%)

06/26/20 JPMorgan
Bayer price target raised to EUR 77 from EUR 75 at JPMorgan
06/26/20 Deutsche Bank
Bayer price target raised to EUR 87 from EUR 85 at Deutsche Bank
06/25/20 Morgan Stanley
Bayer price target raised to EUR 88 from EUR 83 at Morgan Stanley
06/25/20 HSBC
HSBC upgrades Bayer to Buy after settlement on most Monsanto cases in U.S.
BMY Bristol-Myers
$59.58 /

-0.72 (-1.19%)

06/22/20 Morgan Stanley
Morgan Stanley sees Eliquis patent being upheld, ruling being 'imminent'
06/08/20 Bernstein
Gilead, AstraZeneca merger would make sense on economic basis, says Bernstein
06/02/20 Credit Suisse
Arena Pharmaceuticals price target raised to $87 from $77 at Credit Suisse
06/02/20 Cantor Fitzgerald
Arena Pharmaceuticals price target raised to $88 from $68 at Cantor Fitzgerald
GSK GlaxoSmithKline
$40.72 /

+0.34 (+0.84%)

06/19/20 Barclays
Glaxo belantamab AdCom a surprise, supports cautious view, says Barclays
06/16/20 Roth Capital
Ideaya Biosciences price target raised to $23 from $12 at Roth Capital
05/14/20 UBS
GlaxoSmithKline price target raised to 1,920 GBp from 1,900 GBp at UBS
IPSEY Ipsen
$0.00 /

+ (+0.00%)

06/08/20 Bryan Garnier
Ipsen upgraded to Buy from Neutral at Bryan Garnier
06/01/20 Barclays
Ipsen price target raised to EUR 72 from EUR 62 at Barclays
06/01/20 BofA
Ipsen upgraded to Buy from Neutral at BofA
05/18/20 JPMorgan
Ipsen upgraded to Neutral on Cabometyx potential at JPMorgan
JAZZ Jazz Pharmaceuticals
$107.54 /

-1.18 (-1.09%)

06/23/20 Barclays
Jazz Pharmaceuticals price target raised to $195 from $183 at Barclays
06/01/20 SVB Leerink
Jazz Pharmaceuticals price target raised to $169 from $160 at SVB Leerink
05/06/20 SVB Leerink
Jazz Pharmaceuticals price target lowered to $160 from $169 at SVB Leerink
05/06/20 Oppenheimer
Jazz Pharmaceuticals price target lowered to $132 from $141 at Oppenheimer
JNJ Johnson & Johnson
$143.24 /

+0.43 (+0.30%)

07/06/20 Baird
Cooper Companies downgraded to Neutral, Baird see confluence of issues
07/01/20 JMP Securities
Minerva's seltorexant still 'underappreciated' upside driver, says JMP
05/29/20 H.C. Wainwright
H.C. Wainwright sees path forward for Minerva's roluperidone despite setback
NVS Novartis
$88.12 /

+0.345 (+0.39%)

07/01/20 Piper Sandler
Amgen appeal rules in favor of patent validity, says Piper Sandler
07/01/20 Jefferies
Amgen win on Enbrel patent removes key overhang, says Jefferies
07/01/20 Goldman Sachs
Global Blood Therapeutics upgraded to Buy from Neutral at Goldman Sachs
06/24/20 Morgan Stanley
Novartis' syringe suit not a material threat to Regeneron, says Morgan Stanley
PFE Pfizer
$33.76 /

-0.27 (-0.79%)

07/08/20 Piper Sandler
Opko Health price target raised to $6 from $4 at Piper Sandler
07/08/20 Argus
Pfizer positioned for stronger revenue growth in 2021 and beyond, says Argus
07/07/20 Needham
Vaxcyte initiated with a Buy at Needham
07/02/20 B. Riley FBR
Novavax should be bought on weakness from Pfizer data, says B. Riley FBR
RHHBY Roche
$0.00 /

+ (+0.00%)

07/03/20 AlphaValue
Roche upgraded to Add from Reduce at AlphaValue
06/29/20 Piper Sandler
Herceptin/Perjecta approval another win for Halozyme, says Piper
06/23/20 Guggenheim
Immunomedics could be M&A fit for several large-cap drugmakers, says Guggenheim
06/10/20 SunTrust
Arcus Biosciences price target raised to $45 from $22 at SunTrust
RTRX Retrophin
$20.86 /

-0.04 (-0.19%)

06/16/20 BTIG
Retrophin initiated with a Buy at BTIG
02/25/20 Barclays
Retrophin downgraded to Equal Weight from Overweight at Barclays
01/13/20 JMP Securities
JMP says continues to like Retrophin opportunity
08/23/19 BMO Capital
Retrophin price target lowered to $33 from $38 at BMO Capital
SNY Sanofi
$51.54 /

+0.14 (+0.27%)

07/08/20 Piper Sandler
Piper upgrades Kiadis on 'platform validating' Sanofi deal
07/06/20 Citi
BioMarin price target raised to $148 from $105 at Citi
07/01/20 Roth Capital
Applied Genetic may attract Sanofi takeover interest, says Roth Capital
06/26/20 SunTrust
Translate Bio initiated with a Buy at SunTrust
TAK Takeda Pharmaceutical
$17.49 /

+0.01 (+0.06%)

06/18/20 RBC Capital
Neurocrine price target raised to $135 from $116 at RBC Capital
06/17/20 Oppenheimer
Takeda deal expands Neurocrine's pipeline into psychiatry, says Oppenheimer
04/20/20 SVB Leerink
Ascendis Pharma price target raised to $170 from $152 at SVB Leerink
03/25/20 Piper Sandler
Piper Sandler backs Overweight on 'well capitalized' Exelixis
TEVA Teva
$11.39 /

+0.17 (+1.52%)

07/02/20 Wells Fargo
Emergent BioSolutions price target raised to $93 from $85 at Wells Fargo
06/26/20 William Blair
Pfenex partner CHMP opinion 'material de-risking event,' says William Blair
06/17/20 Stifel
Amarin settlement with Apotex an 'incremental positive,' says Stifel
06/08/20 Guggenheim
Emergent BioSolutions price target lowered to $87 from $101 at Guggenheim
TEVA Teva
$11.39 /

+0.17 (+1.52%)

SNY Sanofi
$51.54 /

+0.14 (+0.27%)

RTRX Retrophin
$20.86 /

-0.04 (-0.19%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$33.76 /

-0.27 (-0.79%)

NVS Novartis
$88.12 /

+0.345 (+0.39%)

JNJ Johnson & Johnson
$143.24 /

+0.43 (+0.30%)

JAZZ Jazz Pharmaceuticals
$107.54 /

-1.18 (-1.09%)

GSK GlaxoSmithKline
$40.72 /

+0.34 (+0.84%)

BMY Bristol-Myers
$59.58 /

-0.72 (-1.19%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$54.19 /

+0.7 (+1.31%)

ABBV AbbVie
$99.28 /

-0.06 (-0.06%)

  • 09
    Jun
TEVA Teva
$11.39 /

+0.17 (+1.52%)

TAK Takeda Pharmaceutical
$17.49 /

+0.01 (+0.06%)

SNY Sanofi
$51.54 /

+0.14 (+0.27%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$33.76 /

-0.27 (-0.79%)

NVS Novartis
$88.12 /

+0.345 (+0.39%)

JNJ Johnson & Johnson
$143.24 /

+0.43 (+0.30%)

GSK GlaxoSmithKline
$40.72 /

+0.34 (+0.84%)

BMY Bristol-Myers
$59.58 /

-0.72 (-1.19%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$54.19 /

+0.7 (+1.31%)

ABBV AbbVie
$99.28 /

-0.06 (-0.06%)

TEVA Teva
$11.39 /

+0.17 (+1.52%)

SNY Sanofi
$51.54 /

+0.14 (+0.27%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$33.76 /

-0.27 (-0.79%)

NVS Novartis
$88.12 /

+0.345 (+0.39%)

JNJ Johnson & Johnson
$143.24 /

+0.43 (+0.30%)

JAZZ Jazz Pharmaceuticals
$107.54 /

-1.18 (-1.09%)

IPSEY Ipsen
$0.00 /

+ (+0.00%)

GSK GlaxoSmithKline
$40.72 /

+0.34 (+0.84%)

BMY Bristol-Myers
$59.58 /

-0.72 (-1.19%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$54.19 /

+0.7 (+1.31%)

ABBV AbbVie
$99.28 /

-0.06 (-0.06%)

TEVA Teva
$11.39 /

+0.17 (+1.52%)

TAK Takeda Pharmaceutical
$17.49 /

+0.01 (+0.06%)

SNY Sanofi
$51.54 /

+0.14 (+0.27%)

PFE Pfizer
$33.76 /

-0.27 (-0.79%)

NVS Novartis
$88.12 /

+0.345 (+0.39%)

JNJ Johnson & Johnson
$143.24 /

+0.43 (+0.30%)

GSK GlaxoSmithKline
$40.72 /

+0.34 (+0.84%)

BMY Bristol-Myers
$59.58 /

-0.72 (-1.19%)

AZN AstraZeneca
$54.19 /

+0.7 (+1.31%)

ABBV AbbVie
$99.28 /

-0.06 (-0.06%)

Yesterday
On The Fly
Fly Intel: Wall Street's top stories for Wednesday » 16:18
07/08/20
07/08
16:18
07/08/20
16:18
LEVI

Levi Strauss

$12.68 /

-1.195 (-8.62%)

, FB

Facebook

$243.58 /

+2.51 (+1.04%)

, BIIB

Biogen

$280.15 /

+11.97 (+4.46%)

, ALL

Allstate

$88.20 /

-4.38 (-4.73%)

, NGHC

National General

$33.73 /

+13.29 (+65.02%)

, TWTR

Twitter

$35.39 /

+2.41 (+7.31%)

, MRNA

Moderna

$61.58 /

+0.5 (+0.82%)

, GM

General Motors

$24.93 /

-0.19 (-0.76%)

, FCAU

Fiat Chrysler

$9.99 /

-0.09 (-0.89%)

, XENT

Intersect ENT

$17.98 /

+4.07 (+29.26%)

, MDT

Medtronic

$91.64 /

-0.05 (-0.05%)

, NKLA

Nikola

$54.03 /

+13.78 (+34.24%)

, GILT

Gilat Satellite

$5.20 /

-0.905 (-14.82%)

, CMTL

Comtech

$15.87 /

+0.32 (+2.06%)

Stocks continue to rise…

Open Full Text

ShowHide Related Items >><<
XENT Intersect ENT
$17.98 /

+4.07 (+29.26%)

TWTR Twitter
$35.39 /

+2.41 (+7.31%)

NKLA Nikola
$54.03 /

+13.78 (+34.24%)

NGHC National General
$33.73 /

+13.29 (+65.02%)

MRNA Moderna
$61.58 /

+0.5 (+0.82%)

MDT Medtronic
$91.64 /

-0.05 (-0.05%)

LEVI Levi Strauss
$12.68 /

-1.195 (-8.62%)

GM General Motors
$24.93 /

-0.19 (-0.76%)

GILT Gilat Satellite
$5.20 /

-0.905 (-14.82%)

FCAU Fiat Chrysler
$9.99 /

-0.09 (-0.89%)

FB Facebook
$243.58 /

+2.51 (+1.04%)

CMTL Comtech
$15.87 /

+0.32 (+2.06%)

BIIB Biogen
$280.15 /

+11.97 (+4.46%)

ALL Allstate
$88.20 /

-4.38 (-4.73%)

LEVI Levi Strauss
$12.68 /

-1.195 (-8.62%)

06/16/20 Exane BNP Paribas
Levi Strauss initiated with an Outperform at Exane BNP Paribas
04/09/20 Guggenheim
Levi Strauss price target lowered to $16 from $26 at Guggenheim
04/08/20 Citi
Levi Strauss has ample liquidity and remains 'strong brand,' says Citi
03/18/20 BofA
Levi Strauss downgraded to Neutral with $15 price target at BofA
FB Facebook
$243.58 /

+2.51 (+1.04%)

08:15 Today Wedbush
Pinterest price target raised to $31 from $26 at Wedbush
07/07/20 BofA
Potential U.S. ban of TikTok could be tailwind to Snap engagement, says BofA
07/01/20 Monness Crespi
Facebook has opportunity to emerge from crisis stronger, says Monness Crespi
07/01/20 Goldman Sachs
Facebook checks show limited impact from ad boycott, says Goldman Sachs
BIIB Biogen
$280.15 /

+11.97 (+4.46%)

07/08/20 Credit Suisse
Biogen submits Aducanumab BLA, upside possible near-term, says Credit Suisse
07/08/20 Stifel
Biogen submission of Aducanumab BLA 'an incremental positive,' says Stifel
07/08/20 Goldman Sachs
Goldman says Biogen BLA submission for Alzheimer's drug an incremental positive
07/08/20 Jefferies
Biogen likely to get Priority Review for aducanumab, says Jefferies
ALL Allstate
$88.20 /

-4.38 (-4.73%)

08:37 Today B. Riley FBR
National General downgraded to Neutral from Buy at B. Riley FBR
06:49 Today Citi
Allstate acquisition of National an incremental positive, says Citi
06:20 Today JMP Securities
National General downgraded to Market Perform from Outperform at JMP Securities
07/08/20 William Blair
National General downgraded to Market Perform from Outperform at William Blair
NGHC National General
$33.73 /

+13.29 (+65.02%)

06:16 Today B. Riley FBR
National General downgraded to Neutral from Buy at B. Riley FBR
TWTR Twitter
$35.39 /

+2.41 (+7.31%)

07:01 Today Citi
Twitter shares overreacted to paid service potential, says Citi
07/08/20 Rosenblatt
Rosenblatt says 'highly unlikely' Twitter considering paid subscription tiers
06/30/20 Morgan Stanley
Morgan Stanley says buy Facebook amid boycott-driven weakness
06/29/20 Stifel
Stifel says Facebook sales won't be materially hurt unless ad boycott broadens
MRNA Moderna
$61.58 /

+0.5 (+0.82%)

07/08/20 Piper Sandler
Piper reiterates $100 target on Moderna after Phase II study enrolled
07/02/20 BMO Capital
Moderna mRNA platform supported by Pfizer vaccine data, says BMO Capital
06/30/20 Argus
Moderna initiated with a Buy at Argus
06/30/20 Argus
Moderna initiated with a Buy at Argus
GM General Motors
$24.93 /

-0.19 (-0.76%)

06/25/20 Morgan Stanley
Talks with Ford dealer highlight inventory risk, says Morgan Stanley
06/24/20 Morgan Stanley
GM electric vehicle business could be worth $100B, says Morgan Stanley
06/19/20 JPMorgan
General Motors price target raised to $33 from $29 at JPMorgan
06/18/20 Jefferies
Jefferies raises price targets for Ford, GM and FCA on balance sheet de-risking
FCAU Fiat Chrysler
$9.99 /

-0.09 (-0.89%)

06/30/20 UBS
Fiat Chrysler price target raised to EUR 9 from EUR 6 at UBS
06/22/20 Redburn
Fiat Chrysler upgraded to Buy from Neutral at Redburn
XENT Intersect ENT
$17.98 /

+4.07 (+29.26%)

07/08/20 Oppenheimer
Takeout bid of $17 for Intersect ENT would be 'reasonable,' says Oppenheimer
06/23/20 Oppenheimer
Intersect ENT initiated with a Perform at Oppenheimer
06/09/20 SVB Leerink
Intersect ENT C-code issuance has 'mixed implications,' says SVB Leerink
06/09/20 Piper Sandler
Intersect ENT's C-Code approval adds access to 40M lives, says Piper Sandler
MDT Medtronic
$91.64 /

-0.05 (-0.05%)

06/30/20 Stifel
Tandem Diabetes target raised to $80 after UnitedHealth coverage news at Stifel
06/30/20 Oppenheimer
UnitedHealth to start covering Tandem insulin pump, says Oppenheimer
06/30/20 Piper Sandler
United Health coverage a 'clear positive' for Tandem, says Piper Sandler
06/18/20 Argus
Medtronic has strong growth opportunities, says Argus
NKLA Nikola
$54.03 /

+13.78 (+34.24%)

07/08/20
Fly Intel: Top five analyst upgrades
07/08/20 JPMorgan
JPMorgan upgrades Nikola to Overweight after 40% July selloff
07/08/20 JPMorgan
Nikola upgraded to Overweight from Neutral at JPMorgan
07/07/20 RBC Capital
Nikola initiated with a Sector Perform at RBC Capital
GILT Gilat Satellite
$5.20 /

-0.905 (-14.82%)

CMTL Comtech
$15.87 /

+0.32 (+2.06%)

06/04/20 Northland
Comtech price target lowered to $24 from $27 at Northland
03/31/20 Citi
Comtech price target lowered to $17 from $34 at Citi
XENT Intersect ENT
$17.98 /

+4.07 (+29.26%)

TWTR Twitter
$35.39 /

+2.41 (+7.31%)

NGHC National General
$33.73 /

+13.29 (+65.02%)

MRNA Moderna
$61.58 /

+0.5 (+0.82%)

MDT Medtronic
$91.64 /

-0.05 (-0.05%)

LEVI Levi Strauss
$12.68 /

-1.195 (-8.62%)

GM General Motors
$24.93 /

-0.19 (-0.76%)

GILT Gilat Satellite
$5.20 /

-0.905 (-14.82%)

FCAU Fiat Chrysler
$9.99 /

-0.09 (-0.89%)

FB Facebook
$243.58 /

+2.51 (+1.04%)

CMTL Comtech
$15.87 /

+0.32 (+2.06%)

BIIB Biogen
$280.15 /

+11.97 (+4.46%)

ALL Allstate
$88.20 /

-4.38 (-4.73%)

  • 19
    May
  • 12
    Feb
XENT Intersect ENT
$17.98 /

+4.07 (+29.26%)

TWTR Twitter
$35.39 /

+2.41 (+7.31%)

NKLA Nikola
$54.03 /

+13.78 (+34.24%)

MRNA Moderna
$61.58 /

+0.5 (+0.82%)

MDT Medtronic
$91.64 /

-0.05 (-0.05%)

LEVI Levi Strauss
$12.68 /

-1.195 (-8.62%)

GM General Motors
$24.93 /

-0.19 (-0.76%)

GILT Gilat Satellite
$5.20 /

-0.905 (-14.82%)

FB Facebook
$243.58 /

+2.51 (+1.04%)

BIIB Biogen
$280.15 /

+11.97 (+4.46%)

XENT Intersect ENT
$17.98 /

+4.07 (+29.26%)

TWTR Twitter
$35.39 /

+2.41 (+7.31%)

NKLA Nikola
$54.03 /

+13.78 (+34.24%)

MRNA Moderna
$61.58 /

+0.5 (+0.82%)

MDT Medtronic
$91.64 /

-0.05 (-0.05%)

LEVI Levi Strauss
$12.68 /

-1.195 (-8.62%)

GM General Motors
$24.93 /

-0.19 (-0.76%)

FCAU Fiat Chrysler
$9.99 /

-0.09 (-0.89%)

FB Facebook
$243.58 /

+2.51 (+1.04%)

CMTL Comtech
$15.87 /

+0.32 (+2.06%)

BIIB Biogen
$280.15 /

+11.97 (+4.46%)

ALL Allstate
$88.20 /

-4.38 (-4.73%)

TWTR Twitter
$35.39 /

+2.41 (+7.31%)

NKLA Nikola
$54.03 /

+13.78 (+34.24%)

MRNA Moderna
$61.58 /

+0.5 (+0.82%)

MDT Medtronic
$91.64 /

-0.05 (-0.05%)

LEVI Levi Strauss
$12.68 /

-1.195 (-8.62%)

GM General Motors
$24.93 /

-0.19 (-0.76%)

FCAU Fiat Chrysler
$9.99 /

-0.09 (-0.89%)

FB Facebook
$243.58 /

+2.51 (+1.04%)

BIIB Biogen
$280.15 /

+11.97 (+4.46%)

Recommendations
Opko Health price target raised to $6 from $4 at Piper Sandler » 13:08
07/08/20
07/08
13:08
07/08/20
13:08
OPK

Opko Health

$4.03 /

+0.2 (+5.22%)

, PFE

Pfizer

$33.72 /

-0.31 (-0.91%)

Piper Sandler analyst…

Piper Sandler analyst Edward Tenthoff raised the firm's price target on Opko Health (OPK) to $6 from $4 and reiterates an Overweight rating on the shares. The stock in afternoon trading is up 5% to $4.04. The analyst says "continued strong" SARS-CoV-2 PCR and growing antibody testing at BioReference Labs increases his confidence in the company's Service revenue forecast of $225M in Q2 and $896M this year. Further, partner Pfizer (PFE) will file in the Biologics License Application and Market Authorization Application for once-weekly somatrogon for treatment of growth hormone deficiency children this year, Tenthoff tells investors in a research note.

ShowHide Related Items >><<
PFE Pfizer
$33.72 /

-0.31 (-0.91%)

OPK Opko Health
$4.03 /

+0.2 (+5.22%)

OPK Opko Health
$4.03 /

+0.2 (+5.22%)

06/09/20 Piper Sandler
Opko Health price target raised to $4 from $3 at Piper Sandler
06/08/20 Piper Sandler
Opko Health, Pfizer data show IGF-1 normal at ENDO, says Piper Sandler
06/01/20 Piper Sandler
Piper keeps Overweight rating on Opko Health as FDA clears COVID-19 trial start
04/29/20 Piper Sandler
Piper backs Overweight on Opko as BioReference starts COVID-19 antibody testing
PFE Pfizer
$33.72 /

-0.31 (-0.91%)

07/08/20 Argus
Pfizer positioned for stronger revenue growth in 2021 and beyond, says Argus
07/07/20 Needham
Vaxcyte initiated with a Buy at Needham
07/02/20 B. Riley FBR
Novavax should be bought on weakness from Pfizer data, says B. Riley FBR
07/02/20 BMO Capital
Moderna mRNA platform supported by Pfizer vaccine data, says BMO Capital
PFE Pfizer
$33.72 /

-0.31 (-0.91%)

OPK Opko Health
$4.03 /

+0.2 (+5.22%)

  • 25
    Oct
PFE Pfizer
$33.72 /

-0.31 (-0.91%)

OPK Opko Health
$4.03 /

+0.2 (+5.22%)

PFE Pfizer
$33.72 /

-0.31 (-0.91%)

OPK Opko Health
$4.03 /

+0.2 (+5.22%)

PFE Pfizer
$33.72 /

-0.31 (-0.91%)

OPK Opko Health
$4.03 /

+0.2 (+5.22%)

Options
AstraZeneca call volume above normal and directionally bullish » 12:05
07/08/20
07/08
12:05
07/08/20
12:05
AZN

AstraZeneca

$54.51 /

+1.02 (+1.91%)

Bullish option flow…

Bullish option flow detected in AstraZeneca with 25,072 calls trading, 1.9x expected, and implied vol increasing over 1 point to 40.97%. 7/10 weekly 54.5 calls and Jul-20 55 calls are the most active options, with total volume in those strikes near 17,200 contracts. The Put/Call Ratio is 0.02. Earnings are expected on July 30th.

ShowHide Related Items >><<
AZN AstraZeneca
$54.51 /

+1.02 (+1.91%)

AZN AstraZeneca
$54.51 /

+1.02 (+1.91%)

06/24/20 Oddo BHF
AstraZeneca downgraded to Reduce from Buy at Oddo BHF
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
06/10/20 Cowen
AstraZeneca price target raised to $60 from $55 at Cowen
06/10/20 Guggenheim
Merck's bladder cancer failure boosts strategic value of Padcev, says Guggenheim
AZN AstraZeneca
$54.51 /

+1.02 (+1.91%)

AZN AstraZeneca
$54.51 /

+1.02 (+1.91%)

AZN AstraZeneca
$54.51 /

+1.02 (+1.91%)

AZN AstraZeneca
$54.51 /

+1.02 (+1.91%)

Recommendations
Piper reiterates $100 target on Moderna after Phase II study enrolled » 11:38
07/08/20
07/08
11:38
07/08/20
11:38
MRNA

Moderna

$59.65 /

-1.43 (-2.34%)

Piper Sandler analyst…

Piper Sandler analyst Edward Tenthoff reiterates an Overweight rating on Moderna with a $100 price target after the company completed enrollment of 600 subjects in the Phase II study of SARS-CoV-2 vaccine mRNA-1273. The stock in midday trading is down $1.03 to $60.06. Separately, the National Institutes of Health has also completed enrollment of the older adult cohorts with results expected to be published soon, the analyst adds. In addition, Tenthoff finds it important that the National Institute of Allergy and Infectious Diseases/NIH partnered Phase III protocol has been finalized based on FDA feedback and is on-track to begin in July.

ShowHide Related Items >><<
MRNA Moderna
$59.65 /

-1.43 (-2.34%)

MRNA Moderna
$59.65 /

-1.43 (-2.34%)

07/02/20 BMO Capital
Moderna mRNA platform supported by Pfizer vaccine data, says BMO Capital
06/30/20 Argus
Moderna initiated with a Buy at Argus
06/30/20 Argus
Moderna initiated with a Buy at Argus
06/26/20 Morgan Stanley
Morgan Stanley says Axios overstates contention on Moderna-NIH vaccine ownership
MRNA Moderna
$59.65 /

-1.43 (-2.34%)

  • 19
    May
  • 12
    Feb
MRNA Moderna
$59.65 /

-1.43 (-2.34%)

MRNA Moderna
$59.65 /

-1.43 (-2.34%)

MRNA Moderna
$59.65 /

-1.43 (-2.34%)

Downgrade
Fly Intel: Top five analyst downgrades » 10:05
07/08/20
07/08
10:05
07/08/20
10:05
MO

Altria Group

$40.42 /

+0.47 (+1.18%)

, VSTO

Vista Outdoor

$15.20 /

-0.07 (-0.46%)

, HUBS

HubSpot

$232.50 /

-2.535 (-1.08%)

, BAH

Booz Allen

$75.00 /

-0.45 (-0.60%)

, CACI

CACI

$202.99 /

-1.97 (-0.96%)

, NVAX

Novavax

$100.31 /

-4.25 (-4.06%)

Catch up on today's…

Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Altria Group (MO) downgraded to Equal Weight from Overweight at Barclays with analyst Gaurav Jain saying the company is 100% U.S.-exposed and continues to lose market share. 2. Vista Outdoor (VSTO) downgraded to Neutral from Buy at B. Riley FBR with analyst Eric Wold saying the shares have increased by 115% over the past two months. 3. HubSpot (HUBS) downgraded to Neutral from Buy at Mizuho with analyst Siti Panigrahi saying the company has responded to small- and mid-sized businesses being hit hard by COVID-19 with discounts, downgrades, and large promotions. 4. Booz Allen (BAH) and CACI (CACI) were downgraded to Market Perform from Outperform at Raymond James. 5. Novavax (NVAX) downgraded to Neutral from Buy at Ladenburg with analyst Michael Higgins citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
VSTO Vista Outdoor
$15.20 /

-0.07 (-0.46%)

NVAX Novavax
$100.31 /

-4.25 (-4.06%)

MO Altria Group
$40.42 /

+0.47 (+1.18%)

CACI CACI
$202.99 /

-1.97 (-0.96%)

BAH Booz Allen
$75.00 /

-0.45 (-0.60%)

MO Altria Group
$40.42 /

+0.47 (+1.18%)

07/08/20 Barclays
Altria downgraded to Equal Weight on share losses at Barclays
07/08/20 Barclays
Altria Group downgraded to Equal Weight from Overweight at Barclays
07/07/20 Stifel
IQOS reduced exposure claim a 'win' for Philip Morris, Altria, says Stifel
04/20/20 Deutsche Bank
Altria Group price target lowered to $51 from $56 at Deutsche Bank
VSTO Vista Outdoor
$15.20 /

-0.07 (-0.46%)

07/08/20 B. Riley FBR
Vista Outdoor downgraded to Neutral after 115% rally at B. Riley FBR
07/08/20 B. Riley FBR
Vista Outdoor downgraded to Neutral from Buy at B. Riley FBR
07/07/20 Lake Street
Vista Outdoor price target raised to $18 from $13 at Lake Street
06/25/20 Monness Crespi
Vista Outdoor price target raised to $15 from $12 at Monness Crespi
HUBS HubSpot
$232.50 /

-2.535 (-1.08%)

07/08/20 Mizuho
HubSpot downgraded to Neutral on near-term headwinds at Mizuho
07/08/20 Mizuho
HubSpot downgraded to Neutral from Buy at Mizuho
06/29/20 Goldman Sachs
HubSpot price target raised to $263 from $184 at Goldman Sachs
05/07/20 Raymond James
HubSpot price target raised to $190 from $175 at Raymond James
BAH Booz Allen
$75.00 /

-0.45 (-0.60%)

07/08/20 Raymond James
Booz Allen downgraded to Market Perform from Outperform at Raymond James
07/08/20 Raymond James
Booz Allen downgraded to Market Perform from Outperform at Raymond James
06/29/20 William Blair
William Blair says Booz Allen looks to have renewed 2020's biggest expiring deal
06/05/20 William Blair
William Blair back Outperform on Booz Allen after USAF research lab task order
CACI CACI
$202.99 /

-1.97 (-0.96%)

07/08/20 Raymond James
CACI downgraded to Market Perform from Outperform at Raymond James
07/08/20 Raymond James
CACI downgraded to Market Perform from Outperform at Raymond James
06/12/20 William Blair
William Blair sees near-term takeover of Perspecta as unlikely despite Jana news
05/04/20 Wells Fargo
Leidos price target raised to $114 from $105 at Wells Fargo
NVAX Novavax
$100.31 /

-4.25 (-4.06%)

07/08/20 Ladenburg
Novavax downgraded to Neutral from Buy at Ladenburg
07/07/20 Cantor Fitzgerald
Novavax price target raised to $148 from $88 at Cantor Fitzgerald
07/02/20 B. Riley FBR
Novavax should be bought on weakness from Pfizer data, says B. Riley FBR
06/29/20 B. Riley FBR
Novavax price target raised to $106 from $74 at B. Riley FBR
VSTO Vista Outdoor
$15.20 /

-0.07 (-0.46%)

NVAX Novavax
$100.31 /

-4.25 (-4.06%)

MO Altria Group
$40.42 /

+0.47 (+1.18%)

HUBS HubSpot
$232.50 /

-2.535 (-1.08%)

CACI CACI
$202.99 /

-1.97 (-0.96%)

BAH Booz Allen
$75.00 /

-0.45 (-0.60%)

VSTO Vista Outdoor
$15.20 /

-0.07 (-0.46%)

NVAX Novavax
$100.31 /

-4.25 (-4.06%)

MO Altria Group
$40.42 /

+0.47 (+1.18%)

CACI CACI
$202.99 /

-1.97 (-0.96%)

VSTO Vista Outdoor
$15.20 /

-0.07 (-0.46%)

NVAX Novavax
$100.31 /

-4.25 (-4.06%)

MO Altria Group
$40.42 /

+0.47 (+1.18%)

HUBS HubSpot
$232.50 /

-2.535 (-1.08%)

CACI CACI
$202.99 /

-1.97 (-0.96%)

BAH Booz Allen
$75.00 /

-0.45 (-0.60%)

NVAX Novavax
$100.31 /

-4.25 (-4.06%)

MO Altria Group
$40.42 /

+0.47 (+1.18%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.